Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Genasys Inc. | Director | Common Stock | 284K | $526K | $1.85 | Apr 27, 2022 | Direct |
Travere Therapeutics, Inc. | Chief Financial Officer | Common Stock | 35.7K | $319K | $8.96 | May 11, 2022 | Direct |
STANDARD BIOTOOLS INC. | Director | Common Stock | 105K | $266K | $2.54 | Jun 14, 2023 | Direct |
STANDARD BIOTOOLS INC. | Director | Stock Option (Right to Buy) | 35.4K | $132K | $3.74 | Jun 14, 2023 | Direct |
Genasys Inc. | Director | Common Stock | 2K | $3.7K | $1.85 | Apr 27, 2022 | spouse |
Genasys Inc. | Director | Stock Option | 0 | Apr 27, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LAB | STANDARD BIOTOOLS INC. | Jun 14, 2023 | 2 | $0 | 4 | Jun 16, 2023 | Director |
LAB | STANDARD BIOTOOLS INC. | Jun 15, 2022 | 2 | $0 | 4 | Jun 17, 2022 | Director |
TVTX | Travere Therapeutics, Inc. | May 10, 2022 | 2 | -$47.3K | 4 | May 12, 2022 | Chief Financial Officer |
GNSS | Genasys Inc. | Apr 27, 2022 | 2 | $66.5K | 4 | Apr 27, 2022 | Director |
GNSS | Genasys Inc. | Mar 15, 2022 | 1 | $0 | 4 | Mar 17, 2022 | Director |
GNSS | Genasys Inc. | Feb 23, 2022 | 3 | $132 | 4 | Feb 24, 2022 | Director |
TVTX | Travere Therapeutics, Inc. | Jan 31, 2022 | 5 | -$33.9K | 4 | Feb 2, 2022 | Chief Financial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 24, 2022 | 1 | -$51.5K | 4 | Jan 26, 2022 | Chief Financial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 10, 2022 | 2 | -$206K | 4 | Jan 12, 2022 | Chief Financial Officer |
TVTX | Travere Therapeutics, Inc. | Aug 13, 2021 | 2 | -$24.1K | 4 | Aug 17, 2021 | Chief Financial Officer |
LAB | FLUIDIGM CORP | May 25, 2021 | 2 | $0 | 4 | May 27, 2021 | Director |
TVTX | Travere Therapeutics, Inc. | May 11, 2021 | 2 | -$77.2K | 4 | May 13, 2021 | Chief Financial Officer |